Lessons on outcomes-driven weight management models from eMed fund raising

A $200m Series A for US digital health company eMed reveals how AI‑led, outcome‑driven weight management models could shape the future of population health.

Interested in learning more about investment for healthtech innovation? Sign up to the HIN Investment Update.

US digital health company eMed closed a $200 million Series A funding round at a valuation above $2 billion. Led by Aon, the investors included a range of technology and sporting heavy weights, from Tom Brady (eMed Chief Wellness Officer and former NFL star) to Tom Ricketts (Chairman of Chicago Cubs), amongst others. The investment is designed to advance eMed agentic AI platform for employer population health management, with a focus on GLP1 programmes for weight management and diabetes.  

On the surface, it looked like another multimillion headline in a crowded market for US digital lifestyle solutions. But look more closely, and the round tells a story with direct relevance to the UK healthcare system and the next phase of population‑scale digital care. 

The value of hybrid solutions  

eMed provides a hybrid system, bridging together pharmaceutical dispensing and clinical management. The agentic AI‑led platform is designed to not only prescribe GLP‑1s, but to connect clinical, behavioural and operational infrastructure for employer‑based population health. This wrap-around service demonstrates its value through patient adherence numbers and outcomes, rather than sale volumes alone.  

The UK has numerous innovative companies poised to help the health and care system deliver this type of wrap-around care, with companies such as Second Nature, Oviva and Roczen building up evidence as part of the NICE Early Value Assessment process.  

Employers as a helpful testbed 

In the US, employers are where healthcare innovation goes when the insurer system stalls.  

GLP‑1s is becoming a growing employee benefit, yet there are challenges associated with managing access and cost. eMed is bridging the gap between clinical, operational and financial risk. Their upcoming capitated model shifts digital health away from “per‑consultation” economics toward outcome‑linked accountability. 

This model is particularly relevant to health systems like the NHS, where a focus on real behaviour change and long-term measurable outcomes is vital for improved population level outcomes.  

The return of a familiar name  

What eMed appears to have learnt in the US is that population health only works when someone owns the outcome risk. 

eMed acquired Babylon’s remaining UK assets (GP at Hand) before going on to raise this round. Babylon’s original promise in the UK was bold: population health at scale, powered by technology, embedded in the NHS.  

The opportunity for obesity pathways in the UK 

The final takeaway from eMed’s $200m US raise is that capital flows toward innovations that deliver measurable, long-term outcomes. 

The NHS is considering new models for support and deployment of obesity medications, with the Health Innovation Networks already working to support the transformation and evaluation required to ensure adherence and outcomes are measured.  

Obesity pathways in the UK could be commissioned as a wrap-around risk-sharing service, rather than a prescribing exercise. This way, payment could be tied to adherence and metabolic improvement.  

If the UK-based companies can demonstrate their evidence of impact in the NHS and private markets, there is scope for companies to follow in eMed’s footsteps.  

Read more about eMed’s $200m US raise

Subscribe to the HIN Investment Update for key investment news, exclusive insights from the HIN’s investor network, and the latest opportunities and events. Ideal for growing healthtech companies, as well as funders and investors shaping the health innovation ecosystem.